Pasireotide vs TB-500
Overview
Pasireotide is primarily a hormonal peptide, while TB-500 is used for healing & recovery.
This page compares Pasireotide and TB-500 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pasireotide | TB-500 | |
|---|---|---|
| Category | Hormonal | Healing & Recovery |
| Regulatory status (US) | FDA approved | Compounding (Rx) — Apr 2026 |
| Typical dosage | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) | 2-5 mg |
| Frequency | Twice daily (SC formulation) or every 4 weeks (LAR formulation) | weekly |
| Reported benefits | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism | Tissue repair, improved flexibility, reduced inflammation, enhanced recovery, hair growth stimulation |
| Reported side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) | Minimal side effects. Rare: headache, nausea, injection site reactions |
Key differences
Primary use. Pasireotide is categorised under Hormonal, while TB-500 falls under Healing & Recovery. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Pasireotide: FDA-approved. TB-500: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)). TB-500 is typically dosed at 2-5 mg (weekly).
Can you stack them?
Some protocols combine peptides, but stacking Pasireotide and TB-500 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pasireotide and TB-500?
- Pasireotide is primarily a hormonal peptide, while TB-500 is used for healing & recovery. Pasireotide is FDA-approved for one or more indications, whereas TB-500 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- What is TB-500 used for?
- Tissue repair, flexibility, inflammation.
- Can you take Pasireotide and TB-500 together?
- Some users combine peptides within a single protocol, but stacking Pasireotide and TB-500 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pasireotide or TB-500 FDA-approved?
- Pasireotide is FDA-approved for one or more indications. TB-500 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Pasireotide — full monograph: mechanism, research, dosing & references
- TB-500 — full monograph: mechanism, research, dosing & references